T 3011
Alternative Names: B-015; MVR-T3011; MVR-T3011 IT; T-3 - ImmVira Pharma; T-3011Latest Information Update: 19 Jul 2024
At a glance
- Originator Immvira Pharma
- Developer Immvira Pharma; Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Sarcoma
- Phase I/II Non-small cell lung cancer; Solid tumours
- Phase I Ascites; Bladder cancer; Colorectal cancer
- No development reported Skin cancer
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from a phase I/IIa trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 15 Mar 2024 T 3011 receives Fast Track Designation for Head and neck squamous cell cancer (Metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
- 29 Feb 2024 China Medical University and Immvira plans a phase I trial for Colorectal cancer (Monotherapy, Combination therapy, Second-line therapy or greater, Metastatic disease) in April 2024 (Intrahepatic) (NCT06283303)